Pharmacology and Analytical Chemistry Profile of Dapagliflozin, Empagliflozin and Saxagliptin
Clinical Research and Clinical Reports · 2023
DOI: 10.31579/2835-8325/021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research and Clinical Reports, 2023. Verfasst von Mahmoud M. Sebaiy.
Abstract (Originalsprache)
Diabetes mellitus is a worldwide disease that requires special and continuous medical care. Many classes of oral hypoglycemic drugs are currently used; however, the treatment strategy depends on the nature of diabetes type, pharmacological properties of the used drugs in addition to the clinical characteristics of the patient. As such, in this literature review, we will shed the light on the pharmacology and analytical chemistry profile of certain oral hypoglycemic drugs specifically Dapagliflozin, Empagliflozin and Saxagliptin that got attention in the last decade. Mode of action and most of up-to-date reported methods that have been developed for determination of these important anti-diabetic drugs in their pure form, combined form with other drugs, combined form with degradation products, and in biological samples are mentioned in detail.
Zitieren
APA
Sebaiy, M. M. (2023). Pharmacology and Analytical Chemistry Profile of Dapagliflozin, Empagliflozin and Saxagliptin. Clinical Research and Clinical Reports. https://doi.org/10.31579/2835-8325/021
Vancouver
Sebaiy MM. Pharmacology and Analytical Chemistry Profile of Dapagliflozin, Empagliflozin and Saxagliptin. Clinical Research and Clinical Reports. 2023. doi:10.31579/2835-8325/021
BibTeX
@article{Sebaiy2023,
author = {Sebaiy, Mahmoud M.},
title = {Pharmacology and Analytical Chemistry Profile of Dapagliflozin, Empagliflozin and Saxagliptin},
journal = {Clinical Research and Clinical Reports},
year = {2023},
doi = {10.31579/2835-8325/021}
}
EUVIMED